COMBINATION THERAPY WITH NOTCH AND PI3K/MTOR INHIBITORS FOR USE IN TREATMENT OF CANCER

摘要

FIELD: medicine; pharmaceutics.;SUBSTANCE: group of inventions relates to the treatment of ovarian cancer using 4,4,4-trifluor-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or its pharmaceutically acceptable salt or hydrate (compound A) and 8-[5 -(1-hydroxy-1-methylethyl)pyridine-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinoline-2-one or its pharmaceutically acceptable salt (compound B). Compound A or its pharmaceutically acceptable salt or hydrate are used in an amount from 2.5 mg to 75 mg. Compound B or its pharmaceutically acceptable salt is used in an amount from 75 mg to 250 mg. Compound A and compound B can be used by simultaneous, separate or sequential administration, and can be composed for oral administration. ;EFFECT: combinations of compound A and compound B inhibit tumor growth, demonstrating enhanced efficiency and/or reduced toxicity.;35 cl, 3 tbl, 1 ex